IQVIA Holdings Inc.

IQVIA Holdings Inc.

Compare this stock

IQV Stock Report Card


VolatilityTechnicalsProfitPerformanceEarningsAnalyst Price Targets





IQV returned -8.00% in the last 12 months. Based on SPY's performance of -13.62%, its performance is above average giving it a score of 91 of 100.

Analyst Price Targets



17 analysts offer 12-month price targets for IQV. Together, they have an average target of 277.18, the most optimistic target put IQV at 320 within 12-months and the most pessimistic has IQV at 235.




IQV receives a 75 of 100 based on 14 indicators. 10 are bullish, 3 are bearish.




IQV has missed earnings 0 times in the last 20 quarters.




Out of the last 20 quarters, IQV has had 19 profitable quarters and has increased their profits year over year on 12 of them.




IQV has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

IQVIA Holdings Inc. Summary

New York Stock Exchange / IQV
Diagnostics & Research
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.